david sullivan

Has grant

Johns Hopkins University Bloomberg School of Public Health

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Dual artemisinin action combats resistance

Open Date: 2021-03-18

Close Date: 2026-02-28

Grant: Close

Malaria and Mosquito-borne Diseases

Open Date: 2019-07-01

Close Date: 2024-06-30

Grant: Close

Quantum model repurposing of cethromycin for liver stage malaria

Open Date: 2016-09-01

Close Date: 2019-07-31

Grant: Close

Optimized Combination Antimalarial Drug Therapy

Open Date: 2014-03-15

Close Date: 2020-02-29

Grant: Close

Influence of Iron on Murine Malaria

Open Date: 2009-09-30

Close Date: 2013-07-31

Articles (19)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

david sullivan

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (19)

Erratum for Karaba et al., “Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment”

Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis

Hemozoin-induced IFN-γ production mediates innate immune protection against sporozoite infection

Applying lessons of COVID-19 and other emerging infectious diseases to future outbreaks

Passive immunotherapies for the next influenza pandemic

Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials

Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment

Nonclassical mechanisms to irreversibly suppress β-hematin crystal growth

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1

Outpatient Treatment of Confirmed COVID-19

Plasmodium berghei Purified Hemozoin Associated with DNA Strongly Inhibits P. berghei Liver-Stage Development in BALB/c Mice after Intravenous Inoculation

Absence of pathogenic viruses in COVID-19 convalescent plasma

Lower anti-spike levels in B-cell-depleted patients after convalescent plasma transfusion suggest the need for repeated doses

Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial

Hundred-fold increase in SARS-CoV-2 spike antibody levels over three years in a hospital clinical laboratory

Antiviral combination therapies for persistent COVID-19 in immunocompromised patients

Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Collaborators (6)

Arturo Casadevall

Andrew Karaba

Moises Huaman

Jonathon Senefeld

Sabra Klein

Daniele Focosi

Make your next move.